Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03552471
Title Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications

endometrial cancer

peritoneum cancer

fallopian tube cancer

ovarian cancer

Therapies

Mirvetuximab Soravtansine + Rucaparib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.